Iran's Kidney Market Didn't End the Shortage. It Changed Who Pays for It.
The most important weakness in Wendover Productions' argument is not that Iran's compensated kidney program failed to increase transplantation. It did. The problem is that the video treats the disappearance of a waiting list as evidence that the underlying shortage was solved, without establishing whether patients who could not afford kidneys were still waiting, whether donors were adequately protected, or whether the system remained sustainable.
The distinction matters. A waiting list can disappear because supply increases, but it can also disappear because access is determined by the ability to find and pay a donor. Those are very different achievements.
The waiting list was not eliminated. The definition changed.
The video says that Iran apparently eliminated its kidney waiting list after introducing compensation in 1988. That statement was disputed almost immediately.
A 2007 investigation by The BMJ, titled Kidneys on Demand, found that Iran still had approximately 300 patients waiting for deceased-donor kidneys. Patients seeking living donors typically waited two to three months, provided they could access the system and afford the additional payment. Many dialysis patients were not even registered for transplantation.
PMC
The investigation uncovered a more serious problem: Iran's reported kidney-failure population was incomplete. Rural patients and people in smaller towns were sometimes neither diagnosed nor referred for dialysis, meaning they never appeared on the transplant waiting list. Even Ahad Ghods, a leading defender of the Iranian model, acknowledged that this undercount helped explain why the list appeared to disappear.
This was not a minor qualification. It meant the country could report an empty queue without demonstrating that everyone who needed a kidney had received one.
The contradiction became harder to ignore in 2014. A report by officials from Iran's Ministry of Health, published in the Iranian Journal of Kidney Diseases, recorded 17,910 patients waiting for kidney transplants in 2011, against 2,273 kidney transplants performed that year. The authors explicitly described a waiting list that had never disappeared and was growing.
CiteSeerX
The original video was published in August 2020. This was not information that emerged afterward. The BMJ investigation was already 13 years old, and the government-affiliated transplant report was six years old.
The $4,500 figure is plausible. The explanation is incomplete.
The video did not invent the payment figure. Its cited Associated Press report from August 2016 describes compensation of approximately $4,500, with the government covering transplant surgery and donors receiving health coverage for at least a year. However, that same report says finding a donor could take up to six months and that recipients and donors negotiated their financial arrangements before surgery.
STAT
Research published in Transplant International in 2022 provides a much clearer picture. Researchers examined 436 donor-recipient pairs in Mashhad between 2011 and 2018. The average actual kidney price was approximately $4,400, compared with an average official minimum price of approximately $3,200.
PMC
The distinction is important: the government established a minimum payment, not a single fixed price that eliminated bargaining. Additional payments were negotiated between recipients and donors. The research also found that education levels and the age difference between buyer and donor influenced the price.
The market was not uniform across Iran, either. Mashhad had unusually transparent payment records because its Kidney Foundation documented additional payments. Comparable information was unavailable from major markets such as Tehran, Shiraz and Kermanshah. The study therefore cannot establish that its findings represent the entire country.
PMC
The arrangement has continued to evolve. A 2025 account of the Iranian system reports that, in 2024, the official government payment was approximately $1,400, with an additional unofficial payment negotiated between recipient and donor, typically several times higher. The Kidney Patients Advocacy Association can help recipients who cannot afford those additional payments.
PMC
This is considerably more complicated than simply paying everyone $4,500.
There is another important qualification. The Mashhad study found that 47% of recipients were unemployed. That complicates the simplistic assumption that every buyer is wealthy and every seller is poor. Nevertheless, the paid living-donor market operates on a first-come-first-served basis rather than prioritizing recipients according to medical urgency. Charity assistance does not establish that everyone has equal access.
PMC+1
The donors' economic circumstances deserve more attention.
A multicenter study published in 2007 examined 478 living-unrelated kidney donors across 30 Iranian transplant centers.
Its findings were revealing:
- 62% lived below the poverty line.
- Financial difficulties were the most frequently reported motivation for donating.
- 29% were unemployed.
- 79% were the main breadwinners in their households.
- 91% reported satisfaction with their decision to donate.
The last figure matters. These donors were not necessarily unhappy or unwilling participants. But their satisfaction does not remove the underlying economic vulnerability.
PubMed
The question is whether the compensation system protects donors after the operation, when the immediate financial reward has already been received.
A 2015 study examining donor health assessments and follow-up found troubling gaps. Researchers had contact information for 388 donors but managed to interview only 60.
Among those interviewed:
- Only 40% recalled being informed about the risks and benefits of donation.
- 34% had not received instructions about monitoring their health afterward.
- 50% reported receiving no follow-up after donation.
The small response rate of 15.4% means these findings cannot represent every Iranian donor. Nevertheless, they expose a serious weakness in the available aftercare evidence.
PubMed
There is counterevidence worth acknowledging. Another study followed 1,549 Iranian donors for 18–48 months and concluded that their overall health was comparable to that of donors elsewhere. However, it recorded anemia in 47.2%, hyperuricemia in 21.2%, and proteinuria in 13.7%. Its follow-up period also cannot establish lifelong outcomes.
PubMed
The video mentions one year of free health insurance as a safeguard. The AP report actually describes additional discounted coverage in subsequent years. But insurance benefits and reliable medical follow-up are not interchangeable.
A system that pays someone to surrender an organ must demonstrate that it can protect that person for decades, not merely complete the operation successfully.
Iran's success involved more than paying donors.
The episode presents the 1988 compensation program as the central mechanism behind Iran's increased transplant supply. That leaves out a major development: Iran simultaneously built a deceased-donor transplantation system.
Three developments matter:
- 1989: A religious decree permitted transplantation from brain-dead donors.
- 2000: Parliament passed the Brain Death and Organ Transplantation Act, legally authorizing deceased-donor transplantation.
- 2015: The Iranian Society of Organ Donation (ISOD) was established to promote donation, develop procurement capacity and coordinate transplantation.
The 2025 account of the Iranian system reports that the share of combined kidney and liver transplants from deceased donors rose from 1% in 1999 to 66% in 2023. This was a substantial expansion of a donation pathway that did not depend on buying kidneys from living strangers.
PMC
The latest available international registry figures also demonstrate that Iran now operates a mixed system. Its 2025 records list 1,623 living-donor kidney transplants and 1,452 deceased-donor kidney transplants. The registry attributes its Iranian country data to the Ministry of Health.
irodat.org
The paid living-donor system remains important, but it is no longer the only significant source of kidneys.
There is also a striking contemporary contradiction. The 2025 account reports approximately 32,000 people undergoing dialysis in Iran and estimates that the country needs at least 10,000 kidney transplants annually. It also states that ISOD has established a national transplantation waiting list, now managed by the Ministry of Health.
PMC
The report's authors all disclose membership in ISOD, so this is an important institutional perspective rather than an independent audit. Nevertheless, its figures do not describe a country that has permanently escaped organ scarcity.
The latest transplant counts and the estimated annual need are not perfectly matched measures, but the gap is substantial.
The original source trail contained the missing warnings.
Wendover did publish references for the episode. They included the 2016 Associated Press investigation and a 2008 essay by Rupert Major examining whether Iran's model could be replicated elsewhere.
AYTA
Major's essay explicitly described the elimination of Iran's waiting list as a disputed claim. It discussed the BMJ investigation and acknowledged that the Iranian system had ethical and practical weaknesses.
The AP report also attributed the elimination claim to the Iranian government rather than presenting it as an independently established finding.
These qualifications deserved a place in the narration, especially because the video uses the supposed disappearance of the waiting list as its strongest evidence of success.
This is an editorial omission, not proof of deliberate concealment.
The Skillshare sponsorship was disclosed. There is no evidence that the sponsor had an interest in the organ-transplant argument or influenced the editorial position.
The verdict: Increasing supply is not the same as eliminating scarcity.
Iran's experience demonstrates something important: financial incentives can increase the supply of living kidney donors and enable more patients to receive transplants.
But it does not establish that the system eliminated unmet demand, guaranteed equal access, or consistently protected donors.
The distinction between an empty waiting list and an unmet medical need is fundamental. People who are never diagnosed, never referred, never registered or unable to arrange payment can disappear from the official queue without disappearing from the population that needs treatment.
Iran's own historical records expose that distinction. Its later transplant statistics demonstrate that the country continued investing in other forms of organ donation because compensation alone was not a complete answer.
Wendover identifies a genuine ethical conflict between fairness and supply. But its presentation of Iran makes that conflict look more settled than the evidence permits.
A market can make the queue shorter for those who can enter it. That does not mean everyone who needs a kidney gets one.
That is the difference between a successful transplant program and a solved organ shortage.
References
1. The Broken Economics of Organ Transplants — Wendover Productions, August 11, 2020. Original video under examination.
2. In Iran, Unique System Allows Payments for Kidney Donors — Associated Press / STAT, August 25, 2016. Documents the $4,500 compensation, government arrangements, recipient negotiations and waiting times.
3. Kidneys on Demand — Anne Griffin, BMJ, March 10, 2007. Investigates the disputed waiting-list claim and identifies patients excluded from the reported queue.
4. Paying Kidney Donors: Time to Follow Iran? — Rupert W. L. Major, McGill Journal of Medicine, January 2008. Examines the Iranian model and explicitly discusses the disputed claim that its waiting list disappeared.
5. Outlook of Organ Transplantation in Iran: A Time for Quality Assessment — Alireza Heidary Rouchi, Fatemeh Ghaemi and Mohammad Aghighi, Iranian Journal of Kidney Diseases, May 2014. Reports 17,910 kidney patients waiting in 2011 and documents the continuing shortage.
6. Socioeconomic Status of Iranian Living Unrelated Kidney Donors: A Multicenter Study — T. Malakoutian et al., Transplantation Proceedings, May 2007. Examines the financial circumstances and reported satisfaction of 478 donors.
7. Kidneys for Sale: Empirical Evidence From Iran — Tannaz Moeindarbari and Mehdi Feizi, Transplant International, June 24, 2022. Provides actual donor-recipient payment data from 436 matched pairs in Mashhad.
8. Quality and Quantity of Health Evaluation and the Follow-up of Iranian Living Donors — M. R. Khatami et al., Transplantation Proceedings, May 2015. Identifies shortcomings in donor education and medical follow-up, with a limited survey response rate.
9. A 4-Year Follow-up of Living Unrelated Donors of Kidney Allograft in Iran — Ali Nobakht Haghighi et al., Iranian Journal of Kidney Diseases, July 2015. Provides clinical follow-up data from 1,549 donors and important counterevidence against assuming universal harm.
10. 20 Years Iranian Experience of Organ Donation: Shifting From Compensated Living Unrelated Kidney Transplantation — Ali Nobakht Haghighi et al., Kidney International Reports, January 29, 2025. Documents the development of deceased-donor transplantation, current compensation arrangements and continuing shortages; all authors disclose ISOD membership.
11. Iran: International Registry on Organ Donation and Transplantation — IRODaT, 2025 country statistics, updated October 23, 2026. Provides the latest reported living- and deceased-donor kidney transplant counts.